Urology Research and Consultancy, Miami Beach, FL, USA.
Front Oncol. 2012 Aug 6;2:84. doi: 10.3389/fonc.2012.00084. eCollection 2012.
Multifocal renal cell carcinoma (RCC) has been reported in 5-25% of cases worldwide. Although management of patients with multifocal RCC has not been clearly defined, presence of multifocal renal masses in one kidney and a normal contralateral kidney has often been considered a reason for performing radical nephrectomy. This study reviews the world literature to provide an accurate estimate of the prevalence of multifocal RCC and evaluates the oncologic outcomes of multifocal RCC after exclusion of patients with known hereditary and familial renal syndromes. A PubMed search of the literature was performed for articles in the English language using the following terms for the query: "multifocal RCC," "multifocality and RCC," "multicentric RCC," or "bilateral RCC." The references of the published articles were also reviewed for additional publications. Articles that did not specifically exclude patients with familial RCC or known hereditary RCC syndromes were excluded for estimation of multifocality prevalence and oncologic outcomes. After applying our exclusion criteria, nine articles were selected and form the basis of the current analysis. Weighted averages were used to calculate the prevalence of multifocality. Multifocal RCC was found in 6.8% of cases (373 of 5433 patients). Ipsilateral multifocality was found in 6.8% of cases. Bilateral multifocality was found in 11.7% of cases. Of all cases reported in this study, only 10% underwent partial nephrectomy. The rest of the study cohort underwent radical nephrectomy. The review of the literature showed that the use of nephron-sparing techniques in patients with multifocal disease did not compromise oncologic outcomes, despite the need for reoperation in certain cases. In conclusion, multifocal RCC remains a prevalent entity. Most clinicians still prefer to perform radical nephrectomies in these patients despite proven equivalent oncologic outcomes compared to nephron-sparing techniques. Urologists should be aware of these data when proposing treatment options to patients with multifocal RCC.
多灶性肾细胞癌(RCC)在全球范围内的发生率为 5-25%。尽管多灶性 RCC 患者的治疗方法尚未明确界定,但单侧肾脏存在多灶性肾肿块且对侧肾脏正常,通常被认为是行根治性肾切除术的理由。本研究通过对文献进行综述,旨在提供多灶性 RCC 的准确患病率估计,并评估在排除已知遗传性和家族性肾综合征患者后多灶性 RCC 的肿瘤学结局。使用以下术语对文献进行了英语文献的 PubMed 搜索:“多灶性 RCC”、“多灶性和 RCC”、“多中心 RCC”或“双侧 RCC”。还对已发表文章的参考文献进行了审查,以获取其他出版物。对于未专门排除家族性 RCC 或已知遗传性 RCC 综合征患者的文章,由于估计多灶性患病率和肿瘤学结局而被排除在外。在应用排除标准后,选择了 9 篇文章作为当前分析的基础。使用加权平均值计算多灶性的患病率。在 5433 例患者中,有 6.8%(373 例)发现多灶性病变。同侧多灶性病变的发生率为 6.8%。双侧多灶性病变的发生率为 11.7%。在本研究报告的所有病例中,只有 10%的患者接受了部分肾切除术。研究队列的其余部分患者接受了根治性肾切除术。文献复习表明,尽管某些情况下需要再次手术,但在多灶性疾病患者中使用保肾技术并不会影响肿瘤学结局。总之,多灶性 RCC 仍然是一种常见的疾病。尽管与保肾技术相比,多灶性 RCC 患者的肿瘤学结局相当,但大多数临床医生仍倾向于对这些患者行根治性肾切除术。当向多灶性 RCC 患者提出治疗选择时,泌尿科医生应了解这些数据。